Scholarlink

Background <p>Hepatocellular carcinoma (HCC) prognosis remains poor in advanced stages. Stereotactic body radiation therapy (SBRT) combined with pharmacological agents (targeted therapies/immunotherapies) represents a promising multimodal strategy, but its efficacy and safety require comprehensive evaluation.</p> Methods <p>This meta-analysis included 9 studies (<i>n</i> = 20,812). The adverse event analysis covered the overall adverse event data from 7 studies (<i>n</i> = 583) and grade ≥ 3 adverse events from 4 studies (<i>n</i> = 303). The survival outcome analysis included 9 studies (<i>n</i> = 20,781) and the progression-free survival analysis included 4 studies (<i>n</i> = 424). Hazard ratios (HRs) and risk ratios (RRs) with 95% CIs were calculated via fixed/random effects models.</p> Results <p>Compared with pharmacological agents, SBRT combined with pharmacological agents significantly improved 1-year OS (RR = 1.55, 95% CI:1.40–1.72), 2-year OS (RR = 1.63, 95% CI:1.33–1.99), objective response rate (RR = 1.87, 95% CI:1.52–2.39) and reduced mortality risk (HR = 0.54, 95% CI:0.40–0.72), progression risk (HR = 0.49, 95% CI:0.38–0.63) without increasing overall adverse events (RR = 1.03, 95% CI:0.98–1.09) or grade ≥ 3 toxicities (RR = 1.12, 95% CI:0.92–1.36).</p> Conclusion <p>SBRT combined with pharmacological agents significantly improves survival and tumor response in advanced HCC without increasing overall toxicity. This synergy supports the integration of SBRT into systemic therapy paradigms for HCC.</p> Trial registration <p>PROSPERO CRD420251040157.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of stereotactic body radiation therapy combined with targeted agents and immunotherapies in hepatocellular carcinoma: a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月17日

查看全文
  • Shuaihao Hou,
  • Suqin Hu,
  • Qiong Wu,
  • Haonan Sun,
  • Zhongxuan Fang,
  • Rong Sun,
  • Liqun Wang,
  • Bin Zhou

摘要

Background

Hepatocellular carcinoma (HCC) prognosis remains poor in advanced stages. Stereotactic body radiation therapy (SBRT) combined with pharmacological agents (targeted therapies/immunotherapies) represents a promising multimodal strategy, but its efficacy and safety require comprehensive evaluation.

Methods

This meta-analysis included 9 studies (n = 20,812). The adverse event analysis covered the overall adverse event data from 7 studies (n = 583) and grade ≥ 3 adverse events from 4 studies (n = 303). The survival outcome analysis included 9 studies (n = 20,781) and the progression-free survival analysis included 4 studies (n = 424). Hazard ratios (HRs) and risk ratios (RRs) with 95% CIs were calculated via fixed/random effects models.

Results

Compared with pharmacological agents, SBRT combined with pharmacological agents significantly improved 1-year OS (RR = 1.55, 95% CI:1.40–1.72), 2-year OS (RR = 1.63, 95% CI:1.33–1.99), objective response rate (RR = 1.87, 95% CI:1.52–2.39) and reduced mortality risk (HR = 0.54, 95% CI:0.40–0.72), progression risk (HR = 0.49, 95% CI:0.38–0.63) without increasing overall adverse events (RR = 1.03, 95% CI:0.98–1.09) or grade ≥ 3 toxicities (RR = 1.12, 95% CI:0.92–1.36).

Conclusion

SBRT combined with pharmacological agents significantly improves survival and tumor response in advanced HCC without increasing overall toxicity. This synergy supports the integration of SBRT into systemic therapy paradigms for HCC.

Trial registration

PROSPERO CRD420251040157.